Metformin
Metformin HCl — AMPK Activator & Longevity Drug
What is Metformin?
Metformin is the world's most prescribed diabetes drug and has become one of the most studied longevity compounds in humans. Originally derived from the French lilac (Galega officinalis), it has been used for over 60 years in type 2 diabetes. Large epidemiological studies showing diabetic patients on metformin outliving matched non-diabetics prompted the TAME (Targeting Aging with Metformin) trial — the first human longevity clinical trial.
Metformin activates AMPK (AMP-activated protein kinase) by inhibiting mitochondrial Complex I, which raises the AMP:ATP ratio and signals cellular energy deficit. AMPK activation mimics caloric restriction: increasing autophagy, reducing mTOR activity, improving insulin sensitivity, and reducing cellular senescence. It also directly inhibits gluconeogenesis in the liver, reducing blood glucose independent of insulin.
Research Evidence
Decades of Phase 3 RCT data and the UKPDS trial establish metformin as first-line therapy for T2DM with robust efficacy and safety data spanning 60+ years.
Multiple large cohort studies show T2DM patients on metformin have lower all-cause mortality than matched non-diabetics not on metformin — the key observation driving longevity interest.
The TAME trial is the first FDA-endorsed longevity trial. Results expected 2026-2027. Will provide the first controlled human data on metformin as an anti-aging intervention.
Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution / Preparation
This compound does not require reconstitution — it is available as an oral or pre-mixed formulation.
Frequently Asked Questions
Should healthy people take metformin for longevity?
This is actively debated among longevity researchers. The epidemiological data is compelling. However, metformin may blunt exercise adaptation (reducing some fitness gains), which could offset longevity benefits in active individuals. The TAME trial results will clarify. Currently, many longevity physicians recommend metformin for people with metabolic risk factors or over 50, but have less certainty about its use in healthy, active younger people.
What is the difference between regular and extended-release metformin?
Immediate-release metformin is absorbed quickly and more likely to cause GI side effects (nausea, diarrhea). Extended-release (ER/XR) absorbs slowly with significantly fewer GI effects. Most longevity protocols use ER formulations taken with dinner. The glycemic efficacy is similar.
References
- [1]Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy. Diabetes Obes Metab. 2014;16(11):1165-1173.
- [2]Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article